Japan Tissue Engineering Co., Ltd.

Equities

7774

JP3389610001

Medical Equipment, Supplies & Distribution

Delayed Japan Exchange Other stock markets 10:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
666 ^JPY	+0.91%		+1.99%	+31.62%

2023	Japan Tissue Engineering Co., Ltd. Provide Earnings Guidance for the Fiscal Year Ending March 31, 2024	CI
2023	Japan Tissue Engineering Co., Ltd. Provide Earnings Guidance for the Fiscal Year Ending March 31, 2024	CI

Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023

April 26, 2022 at 02:30 am EDT

Japan Tissue Engineering Co., Ltd. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of ¥2,540 million, operating loss of ¥389 million and net loss of ¥388 million or ¥9.57 per share.

Latest news about Japan Tissue Engineering Co., Ltd.

Japan Tissue Engineering Co., Ltd. Provide Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-10-31	CI
Japan Tissue Engineering Co., Ltd. Provide Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-07-31	CI
Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-31	CI
Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-04-27	CI
Teijin, Japan Tissue Engineering to Team Up with Resilience US for Regenerative Medicine Technologies Development; Shares Climb 16%	23-04-21	MT
Teijin Limited and Japan Tissue Engineering Co., Ltd. Form Business Alliance to Spur Development of New Regenerative Medicine Technologies	23-04-20	CI
Japan Tissue Engineering Obtains Marketing Consent for Vitiligo Treatment	23-03-20	MT
Japan Tissue Engineering Co., Ltd. Announces Marketing Approval for Autologous Cultured Epidermis Maintaining Melanocytes	23-03-17	CI
Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-01-27	CI
Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2022	23-01-27	CI
Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2022	22-10-31	CI
Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-10-31	CI
Japan Index Adds Losses on Economic Uncertainty; Eisai Shares Skyrocket 17% on Favorable Results of Alzheimer's Drug	22-09-28	MT
Teijin, Japan Tissue, Others to Put Medicine Platform; Japan Tissue Shares Fall 4%	22-09-28	MT
Teijin, J-TEC, Mitsui Fudosan and NCC to Establish Regenerative Medicine Platform	22-09-27	CI
Japan Tissue Engineering Concludes an Agreement with ActualEyes	22-08-08	CI
Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-07-27	CI
Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-07-27	CI
Japan Tissue Seeks Marketing Consent for Vitiligo Treatment Product	22-04-28	MT
Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2022	22-04-26	CI
Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023	22-04-26	CI
Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2021	22-01-31	CI
Japan Tissue Engineering Co., Ltd. Announces Earnings Guidance for the Fiscal Year Ending March 31, 2022	22-01-31	CI
Japan Tissue Starts Clinical Trial of Treatment for Dermal Burns	21-11-26	MT
Japan Tissue Engineering Co., Ltd. Announces Start of Clinical Trial for Allogeneic Cultured Epidermis	21-11-24	CI

Chart Japan Tissue Engineering Co., Ltd.

Duration

Period

Chart Japan Tissue Engineering Co., Ltd.

More charts

Company Profile

Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-29 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Japan Tissue Engineering Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
JAPAN TISSUE ENGINEERING CO., LTD.	+31.62%	170M
STRYKER CORPORATION	+13.16%	128B
SMITH & NEPHEW PLC	-8.76%	10.65B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+3.60%	8.82B
INSPIRE MEDICAL SYSTEMS, INC.	+19.75%	7.19B
GLAUKOS CORPORATION	+22.28%	4.99B
AXONICS, INC.	+7.55%	3.4B
ENOVIS CORPORATION	-0.21%	3.03B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-4.80%	2.14B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-4.72%	2B

Medical Devices & Implants